Coronavirus vaccine from Oxford and AstraZeneca shows early promise

Published



A coronavirus vaccine candidate developed by Oxford University in the United Kingdom with pharmaceutical giant AstraZeneca has shown potential in preliminary trials.

Early human trials found that the vaccine candidate appears to be safe and induced an immune response to infection in all 1,077 volunteers, according to findings published Monday in the medical journal the Lancet.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.